MDT Medtronic Plc

Medtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2021

Medtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2021

DUBLIN, Aug. 24, 2020 (GLOBE NEWSWIRE) -- The board of directors of Medtronic plc (NYSE:MDT) on Friday, August 21, 2020, approved the fiscal year 2021 second quarter cash dividend of $0.58 per ordinary share, representing a 7 percent increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in June 2020. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 43 consecutive years. The dividend is payable on October 16, 2020, to shareholders of record at the close of business on September 25, 2020.

About Medtronic

Medtronic plc (), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-





Erika Winkels

Public Relations

Ryan Weispfenning

Investor Relations

EN
24/08/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medtronic Plc

Medtronic Plc: 1 director

A director at Medtronic Plc sold 4,997 shares at 82.170USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

Medtronic, Inc.: Update to credit analysis

Our credit view of this issuer reflects its strong product diversification, constrained by its global pricing pressure and soft hospital admission trends.

Medtronic, Inc.: Update to credit analysis

Medtronic's credit profile reflects its excellent liquidity and strong product diversification, constrained by its elevated leverage, FX headwinds and warning letter in its diabetes segment.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

"Sell in May" Another Reason to Favor Defensives The S&P 500 made a high of 4169 last week, tagging our 4165-4200 resistance range. We still believe 4165-4200 will cap upside in 2023, with a reach to 4300-4325 also within the realm of possibility. Considering limited upside in both scenarios, and with the seasonably weaker "sell in May and go away" period approaching, we continue to recommend higher allocations to defensives including Utilities (XLU, RYU), Consumer Staples (XLP), Health Care (X...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch